Navigation Links
Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
Date:2/17/2010

GREENSBORO, N.C., Feb. 17 /PRNewswire/ -- Stretch marks can make even the most beautiful women feel insecure and self-conscious. Approximately 90% of pregnant women and 70% of adolescent females have stretch marks, and they also commonly occur in people who have lost weight within a brief time period. Although they pose no health risks, stretch marks can cause negative body image issues for women of all shapes and sizes. With new Mederma® Stretch Marks Therapy women now have an effective, clinically proven option to improve the appearance of their stretch marks.

From the makers of #1 doctor-recommended brand for scars for over a decade, Mederma® Stretch Marks Therapy is a patented formula that combines a unique blend of ingredients, including the proprietary botanical extract Cepalin®, hyaluronic acid and centella asiatica leaf extract. This advanced formula is dermatologist tested and clinically proven to reduce discoloration, improve texture and enhance skin's softness, with noticeable improvement in about 4 weeks, and optimum improvement in 12 weeks when used twice daily.

"Stretch marks are very common and occur when the skin is stretched beyond a certain degree, such as during pregnancy or in times of weight increase when the connective tissue can be disrupted and show unattractive red marks on the skin's surface," says Zoe Diana Draelos, MD, a clinical and research dermatologist based in High Point, North Carolina, with a special interest in problems associated with skin, hair and nails. "In the clinical trial, 80% of women noted visible improvement in their stretch marks compared to non treatment, with a trend toward improved elasticity."

"Stretch marks can be a nagging reminder to new moms who have worked hard to lose their baby weight," says Victoria Pericon of Mom Blog Savvymommy.com. "An effective product that could help to improve the appearance of their stretch marks would provide a real confidence boost for these women," she added.

Mederma® Stretch Marks Therapy is effective for all the areas of the body where stretch marks occur, including the arms, abdomen and buttocks. For best results, Mederma® Stretch Marks Therapy should be used as directed twice a day for 12 weeks.

Mederma® Stretch Marks Therapy is sold in a 5.29-oz tube and retails for $39.99. It is now available at CVS, Walgreens and in other drugstores nationwide.

About Mederma®

The Mederma® family of products, including Mederma® Gel, Mederma® Cream plus SPF 30, and Mederma® for Kids, has a long tradition of efficacy. The #1 doctor- and pharmacist-recommended brand for scars, Mederma® helps reduce the appearance of scars resulting from surgery, injury, burns, and acne, making them softer, smoother, and less noticeable. To learn more, visit www.mederma.com.

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma®.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

SOURCE Merz Pharmaceuticals, LLC

RELATED LINKS
http://www.mederma.com

'/>"/>

SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Center has been recognized for adherence to the highest standards of trauma, ... accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among ...
(Date:12/8/2016)... ... 2016 , ... Vida Health, the digital health platform that pairs ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect ... consumers who are managing chronic conditions or simply want to improve their ...
Breaking Medicine News(10 mins):